| Objective:The aim of this experimental study was to investigated the serum D-lactate levels in patients with malignant tumor,and compared with normal controls,to explore the diagnostic value of D-lactic acid in malignant tumors.Methods:Blood was collected from of 111 patients with newly-diagnosed malignant tumor(observation group)and 60 cases of normal control group.Blood was always collected in a fasting state.Malignant tumor cases were excluded diabetes,acute intestinal ischemia and bowel obstruction,short bowel syndrome,chronic pancreatic insufficiency,appendicitis,bacterial,parasitesand and fungal infection,taking nsaids patients.According to the Pico ProbeTMD-Lactate Fluorometric Assay Kit specification,taking advantange of enzymatically oxidizes D-Lactate generating a fluorescent signal(Ex/Em= 535/587 nm),calculated the level of serum D-lactic acid of 111 patients with malignant tumor and 60 normal control group,and conducted statistical analysis.Results:1.Before treatment,the serum D-lactic acid level was significantly higher in malignant tumor patients compared to normal control group,and the difference was significant with the control group(P < 0.001).Further analyzed the serum D-lactic acid level in different types of malignant tumors patients,results showed that lung cancer group compared with gastric cancer,the difference was statistically significant(P=0.009).Lung cancer group compared with colorectal cancer and other types of cancer,gastric cancer compared with colorectal cancer and other types of cancer group,colorectal cancer compared with other types of cancer group,the difference was no statistically significant(P > 0.05).2.According to the CEA markers measured by our department,the results showed that there was no significant difference in the level of serum D-lactic acid between the normal group of CEA and the rising group(P > 0.05).3.After treatment,the serum D-lactic acid level of 35 cases of newly diagnosed patients with malignant tumor was lower than before treatment,the difference was statistically significant(P < 0.001).Further analysised the changes of serum D-lactic acid level of before and after treatment in patients with lung cancer,the statistical results showed that after treatment the change of D-lactate in patients with small cell lung cancer was decreased obviously,the difference was significant(P=0.005).Before and treament,there was no statistically significant in patients with non small cell lung cancer(P >0.05).4.The serum D-lactic acid level of in lung cancer was not significantly associated with gender,smoking status,T stage,lymph node metastasis,and pathological type(P>0.05).The serum D-lactic acid level of in lung cancer was associated with age,distant metastasis and tumor staging(P < 0.05).The level of serum D-lactate in patients with lung adenocarcinoma cancer is not related to EGFR mutation(P>0.05).5.The cut-off of serum D-lactic acid diagnosis in patients with lung cancer is0.1547mmol/L,whether or not to exceed the cut-off margin to determine the specificity and sensitivity of serum D-lactic acid,the sensitivity of serum D-lactic acid is 85.5%,and the specificity is 96.7%.Conclusion:1.The level of serum D-lactic acid in patients with malignant tumors was significantly higher than normal control group,suggested that the detection of serum Dlactic acid can be used as a new serological marker for patients with malignant tumors.2.Before and after the treatment,the level of serum D-lactic acid was different in malignant tumors,suggesting that it could be used as an indicator for the monitoring of malignant tumors.3.The level of serum D-lactic acid in patients with lung cancer was related to the distant metastasis and clinical stage,suggested that the level of serum D-lactic acid was related to the development of lung cancer,and may be an indicator of prognosis and a target for treatment of lung cancer patients. |
PDF Full Text Request